scholarly journals GLYCEMIC AND LIPIDEIC STATUS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

2014 ◽  
Vol 04 (01) ◽  
pp. 009-014
Author(s):  
A. Harish Rao
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Total Cholesterol ◽  
Ldl Cholesterol ◽  
Fasting Glucose ◽  
Hdl Cholesterol ◽  
Serum Levels ◽  
Glucose Levels ◽  
Low Hdl ◽  
One Year

Abstract: Objective: to know the glycemic and lipidaemic status in patients with acute myocardial infarction, and with the secondary objective to know the effect of age, gender, diabetes, smoking, hypertension on fasting glucose and lipid levels. Methods and materials: The 74 patients admitted for acute myocardial infarction during the study period of one year were analysed for fasting glucose values and serum levels of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Results: The mean serum concentrations of total cholesterol, triglycerides, HDL cholesterol and LDL cholesterol were 233.28±45.34, 139.22±41.71, 171.43±36.53 and 27.07±36.53 respectively. Mean levels of total cholesterol, HDL cholesterol, triglycerides and fasting glucose values were not affected by age, gender, BMI, hypertension and smoking. BMI >30kg/m2 was associated with increased levels of total cholesterol(p=0.013) and LDL cholesterol(p=0.014). Also increase LDL cholesterol was seen in male gender(p=0.04). The prevalence of hypercholesterolemia, hypertriglyceridemia and low HDL cholesterol was 82.4%,77% and 78% respectively. Diabetes had no effect on lipid profile. Conclusion: our study highlighted the prevalence of dyslipidemias associated with myocardial infarction but not significant impact of fasting glucose levels.

scholarly journals Vitamin D Levels and Lipid Response to Atorvastatin

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
José Luis Pérez-Castrillón ◽  
Laura Abad Manteca ◽  
Gemma Vega ◽  
Javier del Pino Montes ◽  
Daniel de Luis ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Vitamin D ◽  
Total Cholesterol ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Hydroxyvitamin D ◽  
Vitamin D Levels ◽  
Lipid Response ◽  
High Doses

Adequate vitamin D levels are necessary for good vascular health. 1,25-dihydroxycholecalciferol activates CYP3A4, an enzyme of the cytochrome P450 system, which metabolizes atorvastatin to its main metabolites. The objective of this study was to evaluate the response of cholesterol and triglycerides to atorvastatin according to vitamin D levels. Sixty-three patients with acute myocardial infarction treated with low and high doses of atorvastatin were included. Levels of total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol were measured at baseline and at 12 months of follow-up. Baseline levels of 25-hydroxyvitamin D (25-OHD) were classified as deficient (30 nmol/L), insufficient (30–50 nmol/L), and normal (50 nmol/L). In patients with 25-OHD  nmol/L, there were no significant changes in levels of total cholesterol ( mg/dL versus  mg/dL), triglycerides ( mg/dL versus  mg/dL), and LDL cholesterol ( mg/dL versus 92  mg/dL); whereas patients with insufficient (30–50 nmol/L) and normal vitamin D (50 nmol/L) had a good response to atorvastatin. We suggest that vitamin D concentrations 30 nmol/L may be required for atorvastatin to reduce lipid levels in patients with acute myocardial infarction.

Abstract P347: Serum 25-hydroxy Vitamin D, Cardiovascular Risk Markers, And Incident Myocardial Infarction In A High Risk Community Population

Circulation ◽  
2014 ◽  
Vol 129 (suppl_1) ◽  
Author(s):  
Jaeun Yang ◽  
Christopher Naugler ◽  
Lawrence de Koning
Keyword(s):  
Myocardial Infarction ◽  
Vitamin D ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Ldl Cholesterol ◽  
Fasting Glucose ◽  
Hdl Cholesterol ◽  
Risk Markers ◽  
25 Oh Vitamin D

Background: It is unclear whether vitamin D deficiency is associated with a higher risk of cardiovascular disease, and through what biochemical pathways this could occur. We investigated the relationship between serum 25-OH vitamin D and typical cardiovascular risk markers as well as incident myocardial infarction (MI) in a large group of high-risk individuals from the community of Calgary, Alberta, Canada. Methods: Calgary Laboratory Services databases were queried for age, sex, body mass index (BMI), personal healthcare number (PHN) and first available serum 25-OH vitamin D measure from patients who received an electrocardiogram or urine creatinine clearance test from 2010-2013. Data was linked by PHN to first available laboratory results for total cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, fasting glucose and HbA1c as well as Alberta Health Services hospital discharge data for first myocardial infarction (ICD-10: I21.1-9) occurring after 25-OH vitamin D measurement. Multiple linear and logistic regression were used to examine all associations. Results: There were 36 000-50 000 complete patient records for analysis of each of the risk markers, with a median follow-up of 8-11 months. A 30 mmol/L increase in serum 25-OH vitamin D was associated with significantly (p<0.001) lower total cholesterol (-0.07 mmol/L), LDL cholesterol (-0.06 mmol/L), triglycerides (-0.14 mmol/L), fasting glucose (-0.12 mmol/L), and HbA1c (-0.13% mmol/L), but higher HDL cholesterol (+0.06 mmol/L) after adjusting for age, sex, BMI, monthly hours of sun-exposure and time between measures. Among these individuals, there were 458 cases of MI occurring after 25-OH vitamin D measurement, with a median follow-up of 1 year. In a case-cohort analysis that included 2500 controls, a 30 mmol/L increase in 25-OH vitamin D was associated with a 21% (p<0.001) lower odds of MI after multivariate adjustment. This association was strongly attenuated after adjusting LDL, HDL, fasting glucose and HbA1c. Conclusion: In a high-risk group of community patients from Calgary, Alberta, Canada, higher serum 25-OH vitamin D was associated with a lower risk of MI, which was explained by changes in commonly measured cardiovascular risk markers. Further study is needed to determine whether changes in cardiovascular risk markers are causally related to changes in 25-OH vitamin D.

scholarly journals Diabeteses dyslipidaemia és atherosclerosis

2016 ◽  
Vol 157 (19) ◽  
pp. 746-752 ◽  
Author(s):  
László Márk ◽  
Győző Dani
Keyword(s):  
Diabetes Mellitus ◽  
Myocardial Infarction ◽  
High Risk ◽  
Statin Therapy ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Small Dense Ldl ◽  
Target Values ◽  
Postprandial Triglyceride ◽  
Low Hdl

The incidence and the public health importance of diabetes mellitus are growing continuously. Despite the improvement observed in the latest years, the leading cause of morbidity and mortality of diabetics are cardiovascular diseases. The diagnosis of diabetes mellitus constitutes such a high risk as the known presence of vascular disease. Diabetic dyslipidaemia is characterised by high fasting and postprandial triglyceride levels, low HDL level, and slightly elevated LDL-cholesterol with domination of atherogenic small dense LDL. These are not independent components of the atherogenic dyslipidaemia, but are closely linked to each other. Beside the known harmful effects of low HDL and small dense LDL, recent findings confirmed the atherogenicity of the triglyceride-rich lipoproteins and their remnants. It has been shown that the key of this process is the overproduction and delayed clearance of triglyceride-rich lipoproteins in the liver. In this metabolism the lipoprotein lipase has a determining role; its function is accelerated by ApoA5 and attenuated by ApoC3. The null mutations of the ApoC3 results in a reduced risk of myocardial infarction, the loss-of-function mutation of ApoA5 was associated with a 60% elevation of triglyceride level and 2.2-times increased risk of myocardial infarction. In case of diabetes mellitus, insulin resistance, obesity, metabolic syndrome and chronic kidney disease the non-HDL-cholesterol is a better marker of the risk than the LDL-cholesterol. Its value can be calculated by subtraction of HDL-cholesterol from total cholesterol. Target values of non-HDL-cholesterol can be obtained by adding 0.8 mmol/L to the LDL-cholesterol targets (this means 3.3 mmol/L in high, and 2.6 mmol/L in very high risk patients). The drugs of first choice in the treatment of diabetic dyslipidaemia are statins. Nevertheless, it is known that even if statin therapy is optimal (treated to target), a considerable residual (lipid) risk remains. For its reduction treatment of low HDL-cholesterol and high triglyceride levels is obvious by the administration of fibrates. In addition to statin therapy, fenofibrate can be recommended. Orv. Hetil., 2016, 157(19), 746–752.

scholarly journals Association of PRDM16 rs12409277 and CtBP2 rs1561589 gene polymorphisms with lipid profile of adolescents

2021 ◽  
Author(s):  
Nela Maksimovic ◽  
Vanja Vidovic ◽  
Tatjana Damnjanovic ◽  
Biljana Jekic ◽  
Nada Majkic Singh ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Lipid Profile ◽  
Total Cholesterol ◽  
Ldl Cholesterol ◽  
Fasting Glucose ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Cholesterol Levels ◽  
Brown Adipose

IntroductionPositive regulatory domain containing 16 (PRDM16) protein represents the key regulator of brown adipose tissue (BAT) development. It induces brown fat phenotype and represses white adipose tissue specific genes through the association with C-terminal binding co-repressor proteins (CtBP1 and CtBP2). In healthy adults presence of BAT has been associated with lower glucose, total cholesterol and LDL (low-density lipoprotein) cholesterol levels. Our aim was to analyze the association of PRDM16 gene (rs12409277) and CtBP2 gene (rs1561589) polymorphisms with body mass index (BMI), fasting glucose level and lipid profile of adolescents.Material and methodsOur study included 295 healthy school children, 145 boys (49.2%) and 150 girls (50.8%), 15 years of age. Genotypes for the selected polymorphisms were detected by the real-time PCR method. Age, gender, height, weight, lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) and fasting glucose levels were recorded.ResultsWe did not find a statistically significant association of rs12409277 and rs1561589 polymorphisms with BMI, fasting glucose and lipid profile of adolescents. We further analyzed the combined effect of the two SNPs and the statistical analysis showed that carriers of CT genotype of rs12409277 polymorphism and GG genotype of rs1561589 polymorphism had significantly lower total cholesterol (p = 0.001) and LDL cholesterol (p = 0.008) levels compared to all other groups of genotypes.ConclusionsOur study suggests that rs12409277 and rs1561589 polymorphism might have an influence on total and LDL cholesterol levels in adolescents. Larger studies should be performed in order to confirm our results.

scholarly journals Acute myocardial infarction in a 17-year-old Bangladeshi boy-possibility of existence of a Bangladeshi paradox

2016 ◽  
Vol 3 (3) ◽  
pp. 62
Author(s):  
Prabir Kumar Das ◽  
F. Hossain ◽  
M.R. Karim
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Hdl Cholesterol ◽  
Anterior Wall ◽  
Emerging Risk ◽  
Low Hdl ◽  
Artery Disease ◽  
Conventional Risk Factors

Coronary artery disease (CAD) and acute myocardial infarction (AMI) are  diseases of older age. AMI is uncommon in young age  and rare in adolescence. A seventeen years old Bangladeshi boy developing acute anterior wall MI is described here. Risk factor analysis for CAD revealed absence of most of the conventional risk factors, like  smoking, diabetes mellitus, hypertension. An  elevated lipoprotein(a) and a low HDL cholesterol  was detected in  blood  which are emerging risk factors  of  CAD  in young Bangladeshis.

scholarly journals Pengaruh jamur tiram putih (pleurotus ostreatus) terhadap kadar glukosa darah, profil lipid dan kadar MDA pada tikus (rattus norvegicus) diabetes melitus

2016 ◽  
Vol 4 (2) ◽  
pp. 131-137 ◽  
Author(s):  
Purbowati Purbowati ◽  
Andrew Johan ◽  
RA Kisdjamiatun RMD
Keyword(s):  
Blood Glucose ◽  
Lipid Profile ◽  
Total Cholesterol ◽  
Pleurotus Ostreatus ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Oyster Mushroom ◽  
Glucose Levels ◽  
Cholesterol Levels ◽  
Blood Glucose Levels

Background : Diabetes mellitus is a chronic disease caused by acquired deficiency in insulin production by the pancreas, or by the ineffectiveness of using the produced insulin. Oyster mushroom (Pleurotus ostreatus) can help lower blood glucose levels, improve lipid profile and reduce levels of MDA.Objective : to analyze the effect of oyster mushroom on blood glucose levels, lipid profile and MDA levels in STZ induced rats as type 1 DM model. Methods : thirty Sprague Dawley rats were randomly divided into 3 groups: one positive group (1) and two treated group which received 100 mg/kgBB (2) and 200 mg/kgBB (3) oyster mushroom extract, respectively. The interventions were carried out for 30 days. The examination of blood glucose levels, lipid profile and MDA levels was before and after the intervention. The differences inthe datapre-post interventions were analyzed by paired t-test, whereas the differences between the groups were analyzed by one-way ANOVA and kruskal wallis followed by post hoc analysis. Results : the treatment group experienced a decrease in blood glucose levels, total cholesterol, LDL cholesterol, triglycerides, MDA and an increase in HDL cholesterol levels post-intervention (p < 0,001). Oyster mushroom extract with the dose of 200 mg/kg was more effective in lowering blood glucose levels, MDA levels and improving lipid profiles (p < 0,001).Conclusion : Oyster mushrooms administration lowers blood glucose levels, total cholesterol, LDL cholesterol, triglycerides, MDA and increases HDL cholesterol levels. 

Low High-Density Lipoprotein Cholesterol to Monitor Long-Term Average Increased Triglycerides

2019 ◽  
Vol 105 (4) ◽  
pp. e1657-e1666 ◽  
Author(s):  
Anne Langsted ◽  
Anne Marie Reimer Jensen ◽  
Anette Varbo ◽  
Børge G Nordestgaard
Keyword(s):  
Myocardial Infarction ◽  
High Density Lipoprotein ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Short Term ◽  
Glucose Levels ◽  
Increased Risk ◽  
Remnant Cholesterol ◽  
Low Hdl

Abstract Context Increased triglyceride-rich remnants represent a causal risk factor for ischemic cardiovascular disease. Objective We tested the hypothesis that low high-density lipoprotein (HDL) cholesterol can be used to monitor long-term high triglycerides/remnant cholesterol, just as high hemoglobin A1c (HbA1c) can be used to monitor long-term high glucose levels. Design, Setting, Participants, and Interventions We studied cross-sectionally 108 731 individuals, dynamically 1313 individuals with lipid measurement at 10 repeated visits, short-term 305 individuals during a fat load, and long-term 10 479 individuals with 2 lipid measurements 10 years apart. Main Outcome Measures Levels of HDL cholesterol and triglycerides. Results Cross-sectionally, HDL cholesterol was inversely associated with triglycerides (R2 = 0.26) and remnant cholesterol (R2 = 0.26). Dynamically, major changes in triglyceride levels from measurement to measurement were mimicked by corresponding modest changes in HDL cholesterol. In the short-term after a fat load, median triglycerides increased 96% while HDL cholesterol decreased only 1%. Long-term, in individuals with measurements 10 years apart, those who initially had the highest triglycerides and corresponding lowest HDL cholesterol, still had highest triglycerides and lowest HDL cholesterol 10 years later. Prospectively, individuals with increased triglycerides/remnant cholesterol had increased risk of myocardial infarction; however, when the HDL cholesterol monitoring was removed, increased triglycerides/remnant cholesterol were largely no longer associated with increased risk of myocardial infarction. Conclusions Low HDL cholesterol is a stable marker of average high triglycerides/remnant cholesterol. This suggests that low HDL cholesterol can be used to monitor long-term average high triglycerides and remnant cholesterol, analogous to high HbA1c as a long-term monitor of average high glucose levels.

scholarly journals Prevalence of Dyslipidaemia and Pre-Diabetes Among Women with Polycystic Ovary Syndrome (PCOS): Do We Overestimate Cardiovascular Risk?

2019 ◽  
Vol 51 (08) ◽  
pp. 539-545
Author(s):  
Krzysztof C. Lewandowski ◽  
Justyna Płusajska ◽  
Wojciech Horzelski ◽  
Andrzej Lewiński
Keyword(s):  
Cardiovascular Risk ◽  
Total Cholesterol ◽  
Glucose Intolerance ◽  
Ldl Cholesterol ◽  
Polycystic Ovary ◽  
Hdl Cholesterol ◽  
Convincing Evidence ◽  
Common Belief ◽  
Low Hdl ◽  
Prevalence Of Obesity

AbstractPCOS is widely accepted as associated with an increased cardiovascular risk, however, without convincing evidence of an increased cardiovascular mortality. We assessed prevalence of obesity, glucose intolerance, and dyslipidaemia in 490 women with PCOS, aged 24.75±8.05 years, diagnosed according to the Rotterdam consensus criteria. Fifty-two percent of women had BMI<26 kg/m2, 81.8% had total cholesterol<200 mg/dl, 82.8% had LDL cholesterol<130 mg/dl (48.3%<100 mg/dl), 81.4% had triglycerides<150 mg/dl, 96.08% had fasting glucose<100 mg/dl, 90.3% had glucose<140 mg/dl at 120′ of OGTT. The most frequent abnormality was low HDL cholesterol, as only 33.9% had LDL>60 mg/dl. Combination of several risk factors related to dyslipidaemia was, however, relatively rare, for example, a combination of raised total cholesterol and LDL cholesterol was present only in 2.9% of subjects. An increase in BMI, total cholesterol, LDL-cholesterol, and glucose concentrations at 120′ of OGTT was more pronounced in women, who had raised concentrations of at least two androgens (n=172, 35.1%), yet there was no increase in insulin resistance parameters, that is, HOMA-IR, QUICKI, McAuley, or Belfiore index. Contrary to common belief, over 50% of women with PCOS have normal body weight, and with exception of lower HDL cholesterol, most have no significant dyslipidaemia or glucose intolerance. Women with normal or borderline abnormal androgens, who form the majority of PCOS subjects, seem to have more healthy metabolic profile. This might be one of the reasons for the absence of evidence of an increased CV mortality in women with PCOS.

Sign in / Sign up

Export Citation Format

Share Document